iagnosis of BRCA1 and BRCA2 is done through genetic testing. Patients who belong to this group are advised to perform breast examinations starting from the age of 18, mammography from the age of 25-35 and regular breast examinations every 6 months or every year as well as magnetic resonance of the breast once in year. It is important not to skip ovarian cancer screenings every 6 months between the ages of 30-35. What precautions should you take? One of the main methods for reducing the risk in these patients is the use of drugs that suppress estrogen, such as tamoxifen or raloxifene, or preventive surgical interventions that reduce the risk.
whether they need genetic
These surgical interventions are referred to as bilateral salpingo-oophorectomy and bilateral prophylactic mastectomy. The use of tamoxifen or raloxifene partially reduces breast cancer. Removing the ovaries in these patients for preventive Rich People Number Data purposes reduces the risk of breast cancer by 50%, while prophylactic mastectomy can reduce this risk by up to 90%. Who should have genetic counseling? Genetic counseling is especially important for women who have a history of breast cancer in their immediate family. Genetic counselors inform these patients screening tests for BRCA1 and BRCA2 and about the medical and psychosocial advantages of these tests. Which patients are considered at risk.
The risk of breast cancer
If you have one or more immediate or distant family. Members with breast cancer, there is a possibility of having hereditary breast cancer. Breast cancer which is France Phone Number List present at a young age from the age of 20-30. Together with ovarian cancer. Means hereditary breast cancer. A very serious risk factor is if your mother or sister has or had breast cancer. Hereditary (inherited or familial) breast cancer is present in 5-10% of all cancer patients. Both the brca1 and brca 2 genes are responsible for 80% of hereditary breast cancers. The risk of cancer in women with brca1 mutations up to the age of 70 is 85%. While the risk of ovarian cancer is 45%. With brca2 genetic mutation is 84%, while the risk of ovarian cancer is 76%.
